MedTrace Logo

Investigator Initiated Study - Asenapine Early Psychosis

NCT01968161 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-01-09

No results posted yet for this study

Summary

We propose a use of a unique facility, the databank at the CNDV, to examine the impact of switching subjects to asenapine in an open-label naturalistic setting. This offers the following advantages: i) providing data on a particularly important population, i.e., subjects who are at the inception of treatment for a psychotic disorder and who are likely to remain on a given drug on a long-term basis; ii) its inclusion in a rich clinical setting, with a clinical team dedicated to provide innovative interventions; iii) its naturalistic design, that will allow to obtain data that will be applicable to "real-life" clinical settings; indeed, subjects who will be switched to asenapine within the current project are those we would switch to this drug in our daily practice.

Conditions

  • Schizophrenia and Disorders With Psychotic Features
  • Disorders

Interventions

DRUG

Asenapine

Sponsors & Collaborators

  • Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec

    lead OTHER

Principal Investigators

  • Marc-André Roy, MD · Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01968161 on ClinicalTrials.gov